SEC Form 4 · accession 0001919246-26-000101
Pelthos Therapeutics Inc. · PTHS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew Pauls
Director
Period of report
Jul 2, 2026
Accepted (ET)
Jul 7, 2026 · 5:03 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001919246
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jul 2, 2026 | S | 692 | $25.9959 | D | 14,458 | D | |
| Common StockF3 | Jul 2, 2026 | S | 94 | $27.3604 | D | 14,364 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer.
- F2This transaction was executed in multiple trades at prices ranging from $25.58 to $26.24. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices ranging from $27.20 to $27.63. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.